RAMSEY, N.J., Jan. 3 /PRNewswire/ -- Alteon Inc. (Amex: ALT) announced
today that Kenneth I. Moch, President and Chief Executive Officer, will
present at the 20th Annual JPMorgan H&Q Healthcare Conference in San
Francisco, California on Tuesday, January 8, 2002 at 1:30 p.m. Pacific Time.
The presentation will be available to the general public via a live web
cast, accessible at
http://php4.eventsdigital.com/events/jpmhq/healthcare2002/index.html. It will
also be archived and available at the investor relations section of Alteon's
web site, http://www.alteonpharma.com later that day.
Mr. Moch will outline Alteon's plans and milestones for 2002, including
the clinical development strategy for its lead product ALT-711, currently in
Phase IIb trials for systolic hypertension.
About Alteon
Alteon is developing several new classes of drugs that reverse or slow
down diseases of aging and complications of diabetes. These compounds impact
a fundamental pathological process caused by protein-glucose complexes called
Advanced Glycosylation End-products (A.G.E.s). The formation and crosslinking
of A.G.E.s are an inevitable part of the aging process that lead to a loss of
flexibility and function in body tissues, organs and vessels. The company is
initially developing therapies for cardiovascular and kidney diseases in older
or diabetic individuals.
Alteon has created a library of novel classes of compounds targeting the
A.G.E. pathway. These include A.G.E. Crosslink Breakers, A.G.E. Formation
Inhibitors and Glucose Lowering Agents. The Company's lead A.G.E. Crosslink
Breaker, ALT-711, is being developed for the treatment of cardiovascular
disorders. ALT-711 is being evaluated in the Phase IIb SAPPHIRE clinical
trial focused on isolated systolic hypertension, and the Phase IIb SILVER
trial in systolic hypertension with left ventricular hypertrophy. The
compound is also under Phase I investigation in end-stage renal disease
patients undergoing peritoneal dialysis, a patient population that has
significant cardiovascular disease. Other A.G.E. compounds are being
evaluated for skin aging, as well as additional human indications and animal
health. For more information on Alteon, visit the company's web site at
http://www.alteonpharma.com.
Any statements contained in this press release that relate to future
plans, events or performance are forward-looking statements that involve risks
and uncertainties including, but not limited to, those relating to technology
and product development (including the possibility that early clinical trial
results may not be predictive of results that will be obtained in large-scale
testing or that any clinical trials will not demonstrate sufficient safety and
efficacy to obtain requisite approvals or will not result in marketable
products), regulatory approval processes, intellectual property rights and
litigation, competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange Commission.
The information contained in this press release is accurate as of the date
indicated. Actual results, events or performance may differ materially.
Alteon undertakes no obligation to publicly release the result of any revision
to these forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
SOURCE Alteon Inc.
 back to top
Related links:
http://www.alteonpharma.com
CONTACT:
Susan M. Pietropaolo, Director, Corporate
Communications & Investor Relations of Alteon Inc.,
+1-201-934-5000, spietropaolo@alteonpharma.com
|
